Activity

Filter

Cancel
Date Panel Item Activity
10 actions
Hereditary Spastic Paraplegia v2.0 NFU1 Gene migrated from ENSG00000169599 to ENSG00000169599 (gene set migration)
Hereditary Spastic Paraplegia v1.84 NFU1 Zornitza Stark Phenotypes for gene: NFU1 were changed from Multiple mitochondrial dysfunctions syndrome 1 (MIM#605711) to Multiple mitochondrial dysfunctions syndrome 1 (MIM#605711); Spastic paraplegia 93, autosomal recessive, MIM# 620938
Hereditary Spastic Paraplegia v1.83 NFU1 Zornitza Stark reviewed gene: NFU1: Rating: GREEN; Mode of pathogenicity: None; Publications: ; Phenotypes: Spastic paraplegia 93, autosomal recessive, MIM# 620938; Mode of inheritance: BIALLELIC, autosomal or pseudoautosomal
Hereditary Spastic Paraplegia v1.54 NFU1 Seb Lunke Marked gene: NFU1 as ready
Hereditary Spastic Paraplegia v1.54 NFU1 Seb Lunke Gene: nfu1 has been classified as Green List (High Evidence).
Hereditary Spastic Paraplegia v1.54 NFU1 Alison Yeung Classified gene: NFU1 as Green List (high evidence)
Hereditary Spastic Paraplegia v1.54 NFU1 Alison Yeung Gene: nfu1 has been classified as Green List (High Evidence).
Hereditary Spastic Paraplegia v1.53 NFU1 Alison Yeung Classified gene: NFU1 as Green List (high evidence)
Hereditary Spastic Paraplegia v1.53 NFU1 Alison Yeung Gene: nfu1 has been classified as Green List (High Evidence).
Hereditary Spastic Paraplegia v1.52 NFU1 Lucy Spencer gene: NFU1 was added
gene: NFU1 was added to Hereditary Spastic Paraplegia - paediatric. Sources: Literature
Mode of inheritance for gene: NFU1 was set to BIALLELIC, autosomal or pseudoautosomal
Publications for gene: NFU1 were set to 36256512
Phenotypes for gene: NFU1 were set to Multiple mitochondrial dysfunctions syndrome 1 (MIM#605711)
Review for gene: NFU1 was set to GREEN
Added comment: Adding to the phenotypic continuum of this gene. 19 affected individuals from 10 independent families with biallelic missense variants associated with a spectrum of early‐onset pure to complex hereditary spastic paraplegia (HSP) phenotype with a longer survival (16/19) on one end and neurodevelopmental delay with severe hypotonia (3/19) on the other.
Sources: Literature